<DOC>
	<DOCNO>NCT00672919</DOCNO>
	<brief_summary>The purpose study measure triglyceride change subject type 2 diabetes mellitus take pioglitazone , daily ( QD ) , follow treatment conversion rosiglitazone .</brief_summary>
	<brief_title>Pioglitazone Study Triglyceride Changes Subjects With Type 2 Diabetes After Conversion From Rosiglitazone .</brief_title>
	<detailed_description>Diabetes mellitus chronic disease multiple metabolic defect result hyperglycemia arise inadequate insulin activity . Type 2 diabetes genetic predisposition , lifestyle , physical habit age play important role determine time onset severity . Type 2 diabetes usually result progression reduce sensitivity hepatic ( liver ) peripheral-tissue cell circulate insulin ( ie , insulin resistance ) progressive inability body produce adequate insulin overcome insulin resistance ( ie , insulin deficiency due beta-cell insufficiency ) result impaired glucose tolerance ultimately overt diabetes . In United States , estimate 15.7 million people diabetes , type 2 diabetes occur approximately 90 95 % case . Therapeutic agent develop address major functional metabolic defect associate type 2 diabetes . Recently introduce drug diabetes therapy thiazolidinedione class . Thiazolidinediones increase glucose utilization , decrease gluconeogenesis increase glucose disposal incompletely understand mechanism one associate bind drug receptor know peroxisomal proliferator-activated receptor . Thiazolidinediones peroxisomal proliferator-activated receptor agonist reduce insulin resistance muscle cell , adipose ( fat ) tissue , hepatic cell ( inhibit hepatic gluconeogenesis ) direct impact insulin secretion . Thus peroxisomal proliferator-activated receptor agonist improve glycemic control result reduce level circulate insulin . Peroxisomal proliferator-activated receptor find various tissue important insulin action , great concentration receptor adipose tissue . Pioglitazone peroxisomal proliferator-activated receptor agonist develop Takeda Chemical Industries , Ltd. ( Osaka , Japan ) . Participation study anticipate approximately 20 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study Has take stable dose rosiglitazone great 90 day prior screen . Has triglyceride level great 200 mg per dL le 1000 mg per dL . Has take stable statin therapy great 90 day prior screen . Has glycosylated hemoglobin le 10.5 % . Type 1 diabetes mellitus . Treated Gemfibrozil within 90 day screen . Previous history cancer , basal cell carcinoma , remission least 5 year prior first dose study drug . The subject alanine aminotransaminase level great 2.5 time upper limit normal , active liver disease , jaundice . Male subject serum creatinine great 2.0 mg per dL female subject serum creatinine great than1.8 mg per dL . Unexplained microscopic hematuria great plus 1 confirmed repeat test . Male subject hemoglobin less 10.5 g per dL female subject hemoglobin less 10.0 g per dL . Significant cardiovascular disease include , limited , New York Heart Association Functional ( Cardiac ) Classification III IV Currently participate another investigational study participate investigational study within past 30 day . Any serious disease condition might affect life expectancy make difficult successfully manage follow subject accord protocol . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Glucocorticoids ( eg . prednisone , cortisone , hydrocortisone , dexamethasone ) exception topical glucocorticoid agent . Gemfibrozil Steroidjoint injection . Thiazolidinediones exception study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>